Revenue
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Amneal Pharmaceuticals, Inc. (AMRX)
Price$17.44Cached quote
Net income
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.02B | $2.79B | $2.39B | $2.21B | $2.09B | $1.99B | $1.63B | $1.66B | $1.03B | $1.02B |
| Gross profit | $1.11B | $1.02B | $820.6M | $784.7M | $769.0M | $628.4M | $353.0M | $716.4M | $526.2M | $597.5M |
| Gross margin | 36.88% | 36.52% | 34.28% | 35.47% | 36.73% | 31.54% | 21.70% | 43.08% | 50.90% | 58.68% |
| Research & development | $186.2M | $190.7M | $163.9M | $195.7M | $201.8M | $179.9M | $188.0M | $194.2M | $171.4M | $179.0M |
| Operating expenses | $719.2M | $771.1M | $616.2M | $879.6M | $616.3M | $537.2M | $601.7M | $736.1M | $281.1M | $312.6M |
| Operating income | $394.1M | $249.3M | $204.4M | −$94.9M | $152.7M | $91.2M | −$248.7M | −$19.7M | $245.1M | $284.9M |
| Operating margin | 13.05% | 8.92% | 8.54% | −4.29% | 7.29% | 4.57% | −15.29% | −1.18% | 23.71% | 27.98% |
| EBITDA | $617.7M | $485.5M | $433.8M | $145.3M | $386.1M | $326.5M | −$41.4M | $188.7M | $360.1M | $317.9M |
| EBITDA margin | 20.46% | 17.38% | 18.12% | 6.57% | 18.44% | 16.39% | −2.55% | 11.35% | 34.83% | 31.22% |
| Net income | $72.1M | −$116.9M | −$84.0M | −$270.6M | $13.2M | $67.8M | −$603.6M | −$19.7M | $0 | $0 |
| Net profit margin | 2.39% | −4.18% | −3.51% | −12.23% | 0.63% | 3.40% | −37.11% | −1.19% | 0.00% | 0.00% |
| Basic EPSper basic share | $0.23 | -$0.38 | -$0.48 | -$0.86 | $0.07 | $0.62 | -$2.74 | -$0.16 | — | — |
| Diluted EPSper diluted share | $0.22 | -$0.38 | -$0.48 | -$0.86 | $0.07 | $0.61 | -$2.74 | -$0.16 | — | — |
Owners
Reported shareholders
≈15.21%of listed shares
Patel Tushar Bhikhubhai48.58M shares · Mar 14, 2025
View holders
| Holder | % owned |
|---|---|
Patel Tushar Bhikhubhai | ≈15.21%48.58M shares |
BlackRock, Inc. | 8.32%26.56M shares |
Patel Chintu | ≈8.19%26.14M shares |
Patel Chirag K. | ≈7.10%22.66M shares |
TPG GP A, LLC | 3.86%12.33M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 3.80%12.14M shares |
Rubric Capital Management LP | 3.18%10.17M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 2.41%7.71M shares |
STATE STREET CORP | 2.30%7.36M shares |
DIMENSIONAL FUND ADVISORS LP | 1.81%5.79M shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.61%5.14M shares |
Assenagon Asset Management S.A. | 1.53%4.89M shares |
Nantahala Capital Management, LLC | 1.42%4.54M shares |
MORGAN STANLEY | 1.29%4.11M shares |
NEUBERGER BERMAN GROUP LLC | 1.22%3.89M shares |
Invesco Ltd. | 1.10%3.5M shares |
Nuveen, LLC | 1.04%3.32M shares |
Allspring Global Investments Holdings, LLC | 1.03%3.3M shares |
GOLDMAN SACHS GROUP INC | 0.94%3.01M shares |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.67%2.15M shares |
Percentages use 319.33M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 11, 2026Form 4 | Autor Deborah M.Director | SellClass A Common Stock | 34.8K | $12.94 | $450.6K | 93.7K |
| Nov 17, 2025Form 4 | Nark Ted CDirector | SellClass A Common Stock | 50.0K | $11.72 | $586.0K | 291.0K |
| Nov 12, 2025Form 4 | Shah NikitaExecutive Vice President | SellClass A Common Stock | 131.9K | $11.92 | $1.57M | 146.4K |
| Aug 27, 2025Form 4 | Kiely JohnDirector | SellClass A Common Stock | 32.0K | $9.23 | $295.4K | 225.4K |
| Aug 25, 2025Form 4 | Shah NikitaExecutive Vice President | SellClass A Common Stock | 6.3K | $9.50 | $60.2K | 146.4K |